Share Price and Basic Stock Data
Last Updated: January 8, 2026, 8:40 pm
| PEG Ratio | 2.16 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lactose (India) Ltd operates within the pharmaceuticals sector, focusing primarily on the production of lactose and related products. The company reported a price of ₹104, with a market capitalization of ₹131 Cr. Over the past fiscal years, Lactose has exhibited strong revenue growth, with sales rising from ₹46 Cr in March 2022 to ₹66 Cr in March 2023, and further increasing to ₹114 Cr in March 2024. The trailing twelve months (TTM) revenue stood at ₹137 Cr, indicating a robust upward trajectory. Quarterly sales trends also reflect this growth, with notable increases such as ₹32.60 Cr in December 2023 and ₹41.18 Cr in September 2025. The operating profit margin (OPM) has fluctuated but remained relatively stable, recorded at 12.77% currently. This performance positions Lactose favorably within the pharmaceutical industry, which generally sees varying margins based on product lines and market demand.
Profitability and Efficiency Metrics
Lactose (India) Ltd has demonstrated commendable profitability metrics, with a reported net profit of ₹5 Cr and an earnings per share (EPS) of ₹4.10 for the year ending March 2025. The return on equity (ROE) stood at 9.69%, while the return on capital employed (ROCE) was reported at 12.9%, indicating effective utilization of equity and capital. The company’s interest coverage ratio (ICR) of 3.02x signifies a healthy capacity to meet interest obligations, reflecting financial stability. However, the operating profit margin has shown variability, with a decline from 27% in March 2022 to 15% in March 2025, which may raise concerns regarding operational efficiency. The cash conversion cycle (CCC) of 165 days suggests that Lactose may have challenges in its working capital management, as it takes longer to convert investments in inventory and receivables back into cash compared to typical industry standards.
Balance Sheet Strength and Financial Ratios
The balance sheet of Lactose (India) Ltd exhibits a mixed picture of strength and potential weakness. As of March 2025, total borrowings amounted to ₹54 Cr against reserves of ₹50 Cr, indicating a slightly leveraged position. The debt-to-equity ratio stood at 0.95x, reflecting a moderate reliance on debt financing. Notably, the company has managed to maintain a current ratio of 1.28, suggesting adequate short-term liquidity. The book value per share has increased to ₹46.66, up from ₹32.22 in March 2023, indicating improved shareholder value. However, the interest coverage ratio of 3.02x, while healthy, shows a slight decline from prior periods, hinting at potential risks in managing financial obligations. The asset turnover ratio of 0.99% suggests that asset efficiency might need improvements to drive higher revenue generation relative to asset base.
Shareholding Pattern and Investor Confidence
Lactose (India) Ltd has a stable shareholding structure, with promoters holding a significant 53.65% stake as of March 2025. This level of promoter ownership can instill confidence among investors, reflecting alignment of interests between management and shareholders. Domestic institutional investors (DIIs) hold a mere 0.62%, indicating limited institutional interest, while the public holds 45.73% of the shares, amounting to 16,810 shareholders. The gradual increase in the number of shareholders from 15,940 in December 2022 to 16,810 by September 2025 suggests growing interest in the company. However, the lack of foreign institutional investment (FIIs) may indicate some hesitation from international investors, which could be a concern for future capital raising. Overall, the stability in promoter holdings and gradual increase in public participation are positive signs for investor confidence.
Outlook, Risks, and Final Insight
The outlook for Lactose (India) Ltd appears cautiously optimistic, supported by a strong revenue growth trajectory and stable profitability metrics. However, risks remain, particularly related to operational efficiency and working capital management, as indicated by the relatively high cash conversion cycle and fluctuating margins. The competitive landscape of the pharmaceuticals sector may also pose challenges, especially as companies innovate and adjust to market demands. Should Lactose improve its operational efficiency and manage its debt levels prudently, it could enhance profitability and shareholder returns. Conversely, failure to address these operational challenges may hinder growth potential and investor sentiment. The company’s ability to navigate these dynamics will be crucial in determining its future performance and market positioning.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 210/84.3 | 28.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,407 Cr. | 404 | 479/192 | 91.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.0 Cr. | 39.6 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,534.77 Cr | 1,143.36 | 52.83 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.17 | 17.02 | 25.99 | 27.47 | 24.43 | 32.60 | 29.40 | 29.46 | 30.45 | 28.72 | 27.77 | 39.58 | 41.18 |
| Expenses | 10.82 | 14.29 | 21.99 | 23.70 | 21.04 | 26.88 | 23.28 | 23.88 | 25.44 | 25.75 | 24.36 | 35.11 | 35.92 |
| Operating Profit | 2.35 | 2.73 | 4.00 | 3.77 | 3.39 | 5.72 | 6.12 | 5.58 | 5.01 | 2.97 | 3.41 | 4.47 | 5.26 |
| OPM % | 17.84% | 16.04% | 15.39% | 13.72% | 13.88% | 17.55% | 20.82% | 18.94% | 16.45% | 10.34% | 12.28% | 11.29% | 12.77% |
| Other Income | 0.20 | 0.16 | 0.14 | 0.28 | 0.26 | 0.28 | 0.31 | 0.22 | 0.30 | 0.56 | 0.37 | 0.41 | 0.37 |
| Interest | 1.31 | 1.55 | 1.84 | 1.55 | 1.31 | 1.21 | 1.17 | 1.26 | 1.37 | 1.64 | 1.84 | 1.22 | 1.04 |
| Depreciation | 1.17 | 1.17 | 1.19 | 1.19 | 1.20 | 1.20 | 1.63 | 1.31 | 1.33 | 1.35 | 1.39 | 1.37 | 1.44 |
| Profit before tax | 0.07 | 0.17 | 1.11 | 1.31 | 1.14 | 3.59 | 3.63 | 3.23 | 2.61 | 0.54 | 0.55 | 2.29 | 3.15 |
| Tax % | -14.29% | 11.76% | 20.72% | 26.72% | 28.95% | 27.02% | 33.88% | 29.72% | 22.22% | 59.26% | -18.18% | 34.50% | 31.11% |
| Net Profit | 0.09 | 0.14 | 0.89 | 0.96 | 0.81 | 2.63 | 2.40 | 2.27 | 2.03 | 0.22 | 0.64 | 1.50 | 2.16 |
| EPS in Rs | 0.07 | 0.11 | 0.71 | 0.76 | 0.64 | 2.09 | 1.91 | 1.80 | 1.61 | 0.17 | 0.51 | 1.19 | 1.72 |
Last Updated: January 6, 2026, 5:38 pm
Below is a detailed analysis of the quarterly data for Lactose (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 41.18 Cr.. The value appears strong and on an upward trend. It has increased from 39.58 Cr. (Jun 2025) to 41.18 Cr., marking an increase of 1.60 Cr..
- For Expenses, as of Sep 2025, the value is 35.92 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 35.11 Cr. (Jun 2025) to 35.92 Cr., marking an increase of 0.81 Cr..
- For Operating Profit, as of Sep 2025, the value is 5.26 Cr.. The value appears strong and on an upward trend. It has increased from 4.47 Cr. (Jun 2025) to 5.26 Cr., marking an increase of 0.79 Cr..
- For OPM %, as of Sep 2025, the value is 12.77%. The value appears strong and on an upward trend. It has increased from 11.29% (Jun 2025) to 12.77%, marking an increase of 1.48%.
- For Other Income, as of Sep 2025, the value is 0.37 Cr.. The value appears to be declining and may need further review. It has decreased from 0.41 Cr. (Jun 2025) to 0.37 Cr., marking a decrease of 0.04 Cr..
- For Interest, as of Sep 2025, the value is 1.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.22 Cr. (Jun 2025) to 1.04 Cr., marking a decrease of 0.18 Cr..
- For Depreciation, as of Sep 2025, the value is 1.44 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.37 Cr. (Jun 2025) to 1.44 Cr., marking an increase of 0.07 Cr..
- For Profit before tax, as of Sep 2025, the value is 3.15 Cr.. The value appears strong and on an upward trend. It has increased from 2.29 Cr. (Jun 2025) to 3.15 Cr., marking an increase of 0.86 Cr..
- For Tax %, as of Sep 2025, the value is 31.11%. The value appears to be improving (decreasing) as expected. It has decreased from 34.50% (Jun 2025) to 31.11%, marking a decrease of 3.39%.
- For Net Profit, as of Sep 2025, the value is 2.16 Cr.. The value appears strong and on an upward trend. It has increased from 1.50 Cr. (Jun 2025) to 2.16 Cr., marking an increase of 0.66 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.72. The value appears strong and on an upward trend. It has increased from 1.19 (Jun 2025) to 1.72, marking an increase of 0.53.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:27 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 24 | 34 | 36 | 31 | 41 | 40 | 35 | 46 | 66 | 114 | 116 | 137 |
| Expenses | 21 | 19 | 24 | 24 | 25 | 31 | 31 | 29 | 34 | 54 | 95 | 99 | 121 |
| Operating Profit | 1 | 5 | 10 | 11 | 6 | 10 | 9 | 6 | 12 | 11 | 19 | 17 | 16 |
| OPM % | 5% | 22% | 30% | 32% | 18% | 24% | 23% | 18% | 27% | 17% | 17% | 15% | 12% |
| Other Income | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Interest | 1 | 3 | 4 | 4 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 6 | 6 |
| Depreciation | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 |
| Profit before tax | 0 | 1 | 4 | 4 | -3 | 1 | 0 | -3 | 3 | 1 | 10 | 7 | 7 |
| Tax % | 60% | 42% | 28% | 36% | -52% | 33% | 30% | -24% | 23% | 18% | 30% | 25% | |
| Net Profit | 0 | 0 | 3 | 3 | -1 | 1 | 0 | -2 | 2 | 1 | 7 | 5 | 5 |
| EPS in Rs | 0.04 | 0.59 | 3.17 | 2.87 | -1.32 | 0.71 | 0.07 | -2.17 | 1.95 | 0.96 | 5.39 | 4.10 | 3.59 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -133.33% | 200.00% | -100.00% | 200.00% | -50.00% | 600.00% | -28.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | 333.33% | -300.00% | 300.00% | -250.00% | 650.00% | -628.57% |
Lactose (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 24% |
| 3 Years: | 36% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 136% |
| 3 Years: | 29% |
| TTM: | -46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 39% |
| 3 Years: | 20% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:55 pm
Balance Sheet
Last Updated: December 10, 2025, 4:35 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 10 | 10 | 10 | 10 | 11 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 7 | 7 | 12 | 17 | 22 | 24 | 24 | 24 | 27 | 28 | 35 | 46 | 50 |
| Borrowings | 23 | 39 | 37 | 34 | 38 | 36 | 39 | 46 | 41 | 38 | 39 | 57 | 54 |
| Other Liabilities | 22 | 25 | 26 | 24 | 13 | 11 | 10 | 7 | 10 | 22 | 14 | 18 | 21 |
| Total Liabilities | 60 | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 | 138 |
| Fixed Assets | 28 | 62 | 61 | 64 | 63 | 60 | 62 | 59 | 59 | 56 | 55 | 52 | 56 |
| CWIP | 15 | 1 | 1 | 1 | 0 | 1 | 0 | 4 | 0 | 0 | 0 | 10 | 12 |
| Investments | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Other Assets | 16 | 15 | 21 | 20 | 19 | 20 | 22 | 25 | 30 | 45 | 46 | 71 | 71 |
| Total Assets | 60 | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 | 138 |
Below is a detailed analysis of the balance sheet data for Lactose (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 4.00 Cr..
- For Borrowings, as of Sep 2025, the value is 54.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 57.00 Cr. (Mar 2025) to 54.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 21.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.00 Cr. (Mar 2025) to 21.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 138.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 133.00 Cr. (Mar 2025) to 138.00 Cr., marking an increase of 5.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 56.00 Cr.. The value appears strong and on an upward trend. It has increased from 52.00 Cr. (Mar 2025) to 56.00 Cr., marking an increase of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 71.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 71.00 Cr..
- For Total Assets, as of Sep 2025, the value is 138.00 Cr.. The value appears strong and on an upward trend. It has increased from 133.00 Cr. (Mar 2025) to 138.00 Cr., marking an increase of 5.00 Cr..
However, the Borrowings (54.00 Cr.) are higher than the Reserves (50.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -22.00 | -34.00 | -27.00 | -23.00 | -32.00 | -26.00 | -30.00 | -40.00 | -29.00 | -27.00 | -20.00 | -40.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 125 | 83 | 96 | 91 | 63 | 62 | 64 | 67 | 90 | 69 | 49 | 68 |
| Inventory Days | 69 | 129 | 344 | 440 | 456 | 384 | 471 | 587 | 343 | 344 | 119 | 171 |
| Days Payable | 308 | 273 | 340 | 559 | 330 | 242 | 202 | 153 | 195 | 275 | 59 | 74 |
| Cash Conversion Cycle | -114 | -61 | 100 | -27 | 188 | 204 | 333 | 501 | 238 | 138 | 109 | 165 |
| Working Capital Days | -59 | -118 | -100 | -107 | 18 | 42 | 59 | 56 | 46 | 56 | 26 | 24 |
| ROCE % | -3% | 8% | 13% | 15% | 4% | 9% | 8% | 3% | 10% | 9% | 18% | 13% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.10 | 5.39 | 0.96 | 2.10 | -2.40 |
| Diluted EPS (Rs.) | 4.06 | 5.39 | 0.96 | 2.10 | -2.40 |
| Cash EPS (Rs.) | 8.38 | 9.54 | 4.68 | 5.57 | 1.64 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 46.66 | 37.41 | 32.22 | 31.20 | 30.68 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 46.66 | 37.41 | 32.22 | 31.20 | 30.68 |
| Revenue From Operations / Share (Rs.) | 92.46 | 90.47 | 52.26 | 36.49 | 30.57 |
| PBDIT / Share (Rs.) | 14.63 | 15.98 | 9.61 | 10.20 | 5.71 |
| PBIT / Share (Rs.) | 10.34 | 11.84 | 5.89 | 6.58 | 1.90 |
| PBT / Share (Rs.) | 5.50 | 7.68 | 1.16 | 2.52 | -2.86 |
| Net Profit / Share (Rs.) | 4.10 | 5.39 | 0.96 | 1.95 | -2.17 |
| PBDIT Margin (%) | 15.81 | 17.66 | 18.38 | 27.95 | 18.69 |
| PBIT Margin (%) | 11.18 | 13.08 | 11.26 | 18.02 | 6.22 |
| PBT Margin (%) | 5.94 | 8.48 | 2.22 | 6.89 | -9.35 |
| Net Profit Margin (%) | 4.43 | 5.96 | 1.83 | 5.33 | -7.08 |
| Return on Networth / Equity (%) | 8.78 | 14.41 | 2.97 | 6.23 | -7.06 |
| Return on Capital Employeed (%) | 14.70 | 19.78 | 9.85 | 10.99 | 2.83 |
| Return On Assets (%) | 3.86 | 6.73 | 1.18 | 2.71 | -2.80 |
| Long Term Debt / Equity (X) | 0.44 | 0.51 | 0.81 | 0.87 | 1.12 |
| Total Debt / Equity (X) | 0.95 | 0.80 | 0.95 | 1.04 | 1.20 |
| Asset Turnover Ratio (%) | 0.99 | 1.12 | 0.68 | 0.51 | 0.40 |
| Current Ratio (X) | 1.28 | 1.40 | 1.41 | 1.53 | 1.69 |
| Quick Ratio (X) | 0.73 | 0.73 | 0.55 | 1.05 | 0.97 |
| Inventory Turnover Ratio (X) | 5.63 | 2.47 | 2.37 | 0.72 | 0.53 |
| Interest Coverage Ratio (X) | 3.02 | 3.84 | 2.03 | 2.51 | 1.20 |
| Interest Coverage Ratio (Post Tax) (X) | 1.85 | 2.30 | 1.20 | 1.48 | 0.54 |
| Enterprise Value (Cr.) | 162.92 | 211.83 | 93.28 | 114.35 | 69.83 |
| EV / Net Operating Revenue (X) | 1.40 | 1.86 | 1.42 | 2.49 | 2.00 |
| EV / EBITDA (X) | 8.85 | 10.53 | 7.71 | 8.91 | 10.68 |
| MarketCap / Net Operating Revenue (X) | 0.95 | 1.54 | 0.84 | 1.64 | 0.87 |
| Price / BV (X) | 1.90 | 3.73 | 1.37 | 1.92 | 0.87 |
| Price / Net Operating Revenue (X) | 0.95 | 1.54 | 0.84 | 1.64 | 0.87 |
| EarningsYield | 0.04 | 0.03 | 0.02 | 0.03 | -0.08 |
After reviewing the key financial ratios for Lactose (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.10. This value is below the healthy minimum of 5. It has decreased from 5.39 (Mar 24) to 4.10, marking a decrease of 1.29.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.06. This value is below the healthy minimum of 5. It has decreased from 5.39 (Mar 24) to 4.06, marking a decrease of 1.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 8.38. This value is within the healthy range. It has decreased from 9.54 (Mar 24) to 8.38, marking a decrease of 1.16.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 46.66. It has increased from 37.41 (Mar 24) to 46.66, marking an increase of 9.25.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 46.66. It has increased from 37.41 (Mar 24) to 46.66, marking an increase of 9.25.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 92.46. It has increased from 90.47 (Mar 24) to 92.46, marking an increase of 1.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 15.98 (Mar 24) to 14.63, marking a decrease of 1.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.34. This value is within the healthy range. It has decreased from 11.84 (Mar 24) to 10.34, marking a decrease of 1.50.
- For PBT / Share (Rs.), as of Mar 25, the value is 5.50. This value is within the healthy range. It has decreased from 7.68 (Mar 24) to 5.50, marking a decrease of 2.18.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.10. This value is within the healthy range. It has decreased from 5.39 (Mar 24) to 4.10, marking a decrease of 1.29.
- For PBDIT Margin (%), as of Mar 25, the value is 15.81. This value is within the healthy range. It has decreased from 17.66 (Mar 24) to 15.81, marking a decrease of 1.85.
- For PBIT Margin (%), as of Mar 25, the value is 11.18. This value is within the healthy range. It has decreased from 13.08 (Mar 24) to 11.18, marking a decrease of 1.90.
- For PBT Margin (%), as of Mar 25, the value is 5.94. This value is below the healthy minimum of 10. It has decreased from 8.48 (Mar 24) to 5.94, marking a decrease of 2.54.
- For Net Profit Margin (%), as of Mar 25, the value is 4.43. This value is below the healthy minimum of 5. It has decreased from 5.96 (Mar 24) to 4.43, marking a decrease of 1.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.78. This value is below the healthy minimum of 15. It has decreased from 14.41 (Mar 24) to 8.78, marking a decrease of 5.63.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.70. This value is within the healthy range. It has decreased from 19.78 (Mar 24) to 14.70, marking a decrease of 5.08.
- For Return On Assets (%), as of Mar 25, the value is 3.86. This value is below the healthy minimum of 5. It has decreased from 6.73 (Mar 24) to 3.86, marking a decrease of 2.87.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.44, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.95. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 0.95, marking an increase of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.99. It has decreased from 1.12 (Mar 24) to 0.99, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 1.5. It has decreased from 1.40 (Mar 24) to 1.28, marking a decrease of 0.12.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.73.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.63. This value is within the healthy range. It has increased from 2.47 (Mar 24) to 5.63, marking an increase of 3.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.02. This value is within the healthy range. It has decreased from 3.84 (Mar 24) to 3.02, marking a decrease of 0.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.85. This value is below the healthy minimum of 3. It has decreased from 2.30 (Mar 24) to 1.85, marking a decrease of 0.45.
- For Enterprise Value (Cr.), as of Mar 25, the value is 162.92. It has decreased from 211.83 (Mar 24) to 162.92, marking a decrease of 48.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has decreased from 1.86 (Mar 24) to 1.40, marking a decrease of 0.46.
- For EV / EBITDA (X), as of Mar 25, the value is 8.85. This value is within the healthy range. It has decreased from 10.53 (Mar 24) to 8.85, marking a decrease of 1.68.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has decreased from 1.54 (Mar 24) to 0.95, marking a decrease of 0.59.
- For Price / BV (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has decreased from 3.73 (Mar 24) to 1.90, marking a decrease of 1.83.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has decreased from 1.54 (Mar 24) to 0.95, marking a decrease of 0.59.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lactose (India) Ltd:
- Net Profit Margin: 4.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.7% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.78% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28 (Industry average Stock P/E: 52.83)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.95
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Survey No.5,6,7A, Vadodra District Gujarat 391780 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Atul Maheshwari | Managing Director |
| Mrs. Sangita Maheshwari | WholeTime Director & CFO |
| Mr. Dhaval Jayant Soni | Ind. Non-Executive Director |
| Mr. Nandan Srinath | Ind. Non-Executive Director |
| Mr. Chandra Mohan Bhagavatula | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Lactose (India) Ltd?
Lactose (India) Ltd's intrinsic value (as of 08 January 2026) is ₹109.81 which is 9.81% higher the current market price of ₹100.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹126 Cr. market cap, FY2025-2026 high/low of ₹210/84.3, reserves of ₹50 Cr, and liabilities of ₹138 Cr.
What is the Market Cap of Lactose (India) Ltd?
The Market Cap of Lactose (India) Ltd is 126 Cr..
What is the current Stock Price of Lactose (India) Ltd as on 08 January 2026?
The current stock price of Lactose (India) Ltd as on 08 January 2026 is ₹100.
What is the High / Low of Lactose (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lactose (India) Ltd stocks is ₹210/84.3.
What is the Stock P/E of Lactose (India) Ltd?
The Stock P/E of Lactose (India) Ltd is 28.0.
What is the Book Value of Lactose (India) Ltd?
The Book Value of Lactose (India) Ltd is 49.6.
What is the Dividend Yield of Lactose (India) Ltd?
The Dividend Yield of Lactose (India) Ltd is 0.00 %.
What is the ROCE of Lactose (India) Ltd?
The ROCE of Lactose (India) Ltd is 12.9 %.
What is the ROE of Lactose (India) Ltd?
The ROE of Lactose (India) Ltd is 9.69 %.
What is the Face Value of Lactose (India) Ltd?
The Face Value of Lactose (India) Ltd is 10.0.